CompBrief BY VELARION

Companies Q32 Bio Inc.

Q32 Bio CEO salary & total pay, FY2025: $1.6M

Q32 Bio (QTTB) CEO salary, fiscal 2025: Jodie Morrison was paid a salary of $645,600 and $1,558,870 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Q32 Bio Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Jodie Morrison's complete compensation dossier

A PDF and a CSV sent to your email: Jodie Morrison's pay in every fiscal year Q32 Bio Inc. reported it, line by line, with Jodie Morrison's equity grants and Q32 Bio Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$1,558,870CEO Jodie Morrison · source
Say-on-pay support95.27%Latest vote

CEO pay, last three years

  • $6,003,238FY2024
  • $1,558,870FY2025

CEO total pay was $1,558,870 in fiscal 2025, down from $6,003,238 in fiscal 2024.

FY2025: salary $645,600 · bonus $0 · stock awards $335,280 · option awards $220,792

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Q32 Bio Inc. in fiscal 2025?
As disclosed, Jodie Morrison (Chief Executive Officer and Director) was the highest-paid executive at Q32 Bio Inc. in fiscal 2025, with total compensation of $1,558,870.
How did shareholders vote on Q32 Bio Inc.'s executive compensation?
As disclosed, 95.27% of shareholders supported Q32 Bio Inc.'s executive compensation in the latest say-on-pay vote.
How much does Q32 Bio Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Q32 Bio Inc. reported total board compensation of $455,500 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jodie Morrison$645,600$0$335,280$220,792$355,080$0$2,118$1,558,870
Chief Executive Officer and Director
Lee Kalowski565,0000135,25559,122226,00001,770987,147
Chief Financial Officer and President
Shelia Violette455,000095,25037,312182,00004,884774,446
Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jodie Morrison$1,558,870$6,003,238—↓ −4,444,368
Lee Kalowski987,1472,854,009—↓ −1,866,862
Shelia Violette774,446———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program consists of a combination of base salary, non-equity incentive compensation and long-term equity incentives. We have designed our compensation program to reflect competitive levels of compensation for comparable positions in the market including among our peer companies, the historical compensation levels, individual performance, and the achievement of our corporate objectives.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon plc
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Shelia VioletteRSU2025-02-24————$95,250
Lee KalowskiRSU2025-02-24————135,255
Jodie MorrisonRSU2025-02-24————335,280

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Shelia Violette$95,250$0$00.0%
Lee Kalowski135,255000.0%
Jodie Morrison335,280000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Jodie MorrisonOption124,07228,6282.54—
Jodie MorrisonOption117,70934,9912.54—
Jodie MorrisonOption9,1567,7452.54—
Jodie MorrisonOption172,569221,8762.54—
Jodie MorrisonRSU—99,000—340,560
Lee KalowskiOption87,38273,9412.54—
Lee KalowskiRSU—39,938—137,387
Lee KalowskiOption16,901—2.54—
Shelia VioletteOption24,68031,7332.54—
Shelia VioletteRSU—28,125—96,750
Shelia VioletteOption32,891—2.54—
Shelia VioletteOption13,305—2.54—
Shelia VioletteOption17,506—2.54—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mark IwickiIndependent · Board Chair · Audit · Compensation (Chair) · Not standing for re-election$95,000—$134,443——$229,443
Kathleen LaPorteIndependent · Audit (Chair) · Nominating and Corporate Governance64,000—120,096——184,096
Bill Lundberg, M.DIndependent · Compensation · Research and Development (Chair) · Not standing for re-election56,000—123,500——179,500
Mary ThistleIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election59,500—118,237——177,737
David Grayzel, M.DIndependent · Research and Development · Not standing for re-election45,000—121,024——166,024
Isaac Manke, Ph.DIndependent · Compensation · Not standing for re-election46,000—119,003——165,003
Diyong XuIndependent · Nominating and Corporate Governance · Not standing for re-election45,000—118,237——163,237
Arthur Tzianabos, Ph.DNot independent · Research and Development45,000—118,237——163,237
Jodie MorrisonEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$114,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)9,500 / 6,000 / 5,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$455,500
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$455,500

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Q32 Bio as a peer

Companies that benchmark against QTTB

No companies currently name QTTB as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Q32 Bio Inc.2025Jodie Morrison$645,600$335,280$220,792$355,080$1,558,870

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-128,072,067400,598143,38995.27%Passed
20252025-06-137,445,998594,5268,11292.61%Passed
2023——————
2022——————
2021——————
2020——————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
2020——a
2021——b
2019——c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Diyong XuDirector2026-05-28A625,000$8$5,000,000Common, indirectForm 4 ↗
Diyong XuDirector2026-05-28A1,250,000810,000,000Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCDirector2026-05-28A625,00085,000,000Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCDirector2026-05-28A1,250,000810,000,000Common, indirectForm 4 ↗
Arthur TzianabosDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Arthur TzianabosDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Diyong XuDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Diyong XuDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Mark IwickiDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Mark IwickiDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Mary ThistleDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Kathleen LaPorteDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Kathleen LaPorteDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Mary ThistleDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Sven Ante LundbergDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
David S. GrayzelDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
Isaac MankeDirector2026-06-12A9,81000Derivative, Class A CommonForm 4 ↗
David S. GrayzelDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Isaac MankeDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Sven Ante LundbergDirector2026-06-12A10,82600Derivative, Class A CommonForm 4 ↗
Isaac MankeDirector2026-06-30D53,52100Derivative, Class A CommonForm 4 ↗
Isaac MankeDirector2026-06-30A53,5213149,859CommonForm 4 ↗
Jodie MorrisonDirector2026-07-16A132,00000CommonForm 4 ↗
Shelia VioletteChief Scientific Officer2026-07-16A37,50000CommonForm 4 ↗
Lee KalowskiCFO and President2026-07-16A53,25000CommonForm 4 ↗
Jodie MorrisonDirector2026-08-25D9,84517163,033CommonForm 4 ↗
Shelia VioletteChief Scientific Officer2026-08-25D2,7981746,335CommonForm 4 ↗
Lee KalowskiCFO and President2026-08-25D3,9721765,776CommonForm 4 ↗
Lee KalowskiCFO and President2026-10-06D1,301810,824CommonForm 4 ↗
Shelia VioletteChief Scientific Officer2026-10-06D91787,629CommonForm 4 ↗
Jodie MorrisonDirector2026-10-06D3,221826,798CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (53 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Jodie Morrison. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 25. As printed: 1,558,870. View filing ↗
  • Section 01, Lee Kalowski. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 987,147. View filing ↗
  • Section 01, Shelia Violette. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 774,446. View filing ↗
  • Section 03, Shelia Violette RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Lee Kalowski RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Jodie Morrison RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 08, Mark Iwicki. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 229,443. View filing ↗
  • Section 08, Kathleen LaPorte. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 184,096. View filing ↗
  • Section 08, Bill Lundberg, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 179,500. View filing ↗
  • Section 08, Mary Thistle. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 177,737. View filing ↗
  • Section 08, David Grayzel, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 166,024. View filing ↗
  • Section 08, Isaac Manke, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 165,003. View filing ↗
  • Section 08, Diyong Xu. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 163,237. View filing ↗
  • Section 08, Arthur Tzianabos, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 163,237. View filing ↗
  • Section 08, Jodie Morrison. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Diyong Xu 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Diyong Xu 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Arthur Tzianabos 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Arthur Tzianabos 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Diyong Xu 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Diyong Xu 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Iwicki 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Iwicki 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mary Thistle 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kathleen LaPorte 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kathleen LaPorte 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mary Thistle 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven Ante Lundberg 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David S. Grayzel 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Isaac Manke 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David S. Grayzel 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Isaac Manke 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven Ante Lundberg 2026-06-12. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Isaac Manke 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Isaac Manke 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jodie Morrison 2026-07-16. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shelia Violette 2026-07-16. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lee Kalowski 2026-07-16. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jodie Morrison 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shelia Violette 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lee Kalowski 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lee Kalowski 2026-10-06. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shelia Violette 2026-10-06. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jodie Morrison 2026-10-06. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2020 vote. Form 8-K, filed 2020-06-11. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-06-21. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2019 vote. Form 8-K, filed 2019-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 455,500 + equity 0 + all other 0 = 455,500, summed across the director compensation table rows.
  • Q32 Bio Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Q32 Bio Inc.'s own proxy. As printed: 1,558,870. View filing ↗
Get the full report — $299